In recent years, numerous research studies have shown that microgravity is a promising tool for a novel approach to develop and/or improve pharmaceutical compounds and processes either for space purposes or applications on Earth.

As such, space medicinal chemistry was proven to be a potential tool to fight against the epidemic: the first study on COVID-19 drug research in space has recently been carried out on the International Space Station.

Organized by Japan Manned Space Systems Corporation and InnoStudio Inc., the first ever webinar series dedicated to pharmaceutical research and drug discovery in space with both scientific and commercial aspects, is now bringing you the newest results and excellent presentations from this rapidly emerging field, which will be given by reputable, internationally renowned experts and scientists who are, as always, pushing the boundaries of science and technology.

Japan Manned Space Systems Corporation (JAMSS) was founded in 1990. Since then, we have been involved in the operation of Japanese Experiment Module (JEM) and H-II Transfer Vehicle (HTV), the training of astronauts and flight controllers and the implementation of space experiments from very beginning of the International Space Station (ISS) project. We also evaluate and provide advice on safety, reliability and maintainability of hardware and software in space, and are highly acclaimed by people in the space industry who consider JAMSS to be synonymous with safety.

With experience of JEM operations since 2008 when JEM first module was launched, we have moved to the next step of Low Earth Orbit (LEO) utilization. Using the space environment, JAMSS is proceeding with the commercial service of the “space manufacturing” to produce and provide high quality protein crystals for drug discovery support. The service name is “Kirara” meaning shiny in Japanese. This is our first step and JAMSS will expand the services in LEO commercialization era.

When we see beyond ISS, it is expected to become the cornerstone of projects aiming at manned space expeditions to the Moon and Mars in the future. JAMSS will also be taking this enormous step into unchartered territory by acting as a bridge between the Earth and outer space to contribute to humanity and society. JAMSS is the company that “links humans and space.”

Japan Manned Space Systems Corporation (JAMSS) was funded in 1990. Since then, we have been involved in the operation of Japanese Experiment Module (JEM) and H-II Transfer Vehicle (HTV), the training of astronauts and flight controllers and the implementation of space experiments from very beginning of the International Space Station (ISS) project. We also evaluate and provide advice on safety, reliability and maintainability of hardware and software in space, and are highly acclaimed by people in the space industry who consider JAMSS to be synonymous with safety.

With experience of JEM operations since 2008 when JEM first module was launched, we have moved to the next step of Low Earth Orbit (LEO) utilization. Using the space environment, JAMSS is proceeding with the commercial service of the “space manufacturing” to produce and provide high quality protein crystals for drug discovery support. The service name is “Kirara” meaning shiny in Japanese. This is our first step and JAMSS will expand the services in LEO commercialization era.

When we see beyond ISS, it is expected to become the cornerstone of projects aiming at manned space expeditions to the Moon and Mars in the future. JAMSS will also be taking this enormous step into unchartered territory by acting as a bridge between the Earth and outer space to contribute to humanity and society. JAMSS is the company that “links humans and space.”

InnoStudio Inc. is a member of the Darholding/ThalesNano global organization, one of the largest upstream technology networks in the Central European region, now with over 150 employees and corporate headquarters in Europe and USA. The holding’s companies with chemistry driven key research, provide products and services to more than 2,000 customers in 75 countries.

InnoStudio’s lead activities include the development of flow chemical reactors for space and pharmaceutical applications, chemical formulation methods in microgravity, and nanotechnology for agrochemical innovation.

The company is the co-founder of the Space Chemistry Consortium (2016), which currently has 40 academic and industrial members from 5 continents. InnoStudio is also the co-organizer of the Space Chemistry Symposium series since 2017, under the umbrella of the American Chemical Society. One of the first scientific papers at the field was published by InnoStudio in Nature Reviews Chemistry (2017).

In December 2019, InnoStudio was the first in the world to carry out nanomolecular chemical synthesis experiments on the International Space Station, which provided promising results for the development and manufacturing of novel active ingredients for the pharmaceutical, cosmetics, and agrochemical sectors. InnoStudio, together with CycloLab was also the first to investigate the possible effects of microgravity on the remdesivir-SBECD interaction, one of the most promising drugs for the treatment of COVID-19.

InnoStudio Inc. is a member of the Darholding/ThalesNano global organization, one of the largest upstream technology networks in the Central European region, now with over 150 employees and corporate headquarters in Europe and USA. The holding’s companies with chemistry driven key research, provide products and services to more than 2,000 customers in 75 countries.

InnoStudio’s lead activities include the development of flow chemical reactors for space and pharmaceutical applications, chemical formulation methods in microgravity, and nanotechnology for agrochemical innovation.

The company is the co-founder of the Space Chemistry Consortium (2016), which currently has 40 academic and industrial members from 5 continents. InnoStudio is also the co-organizer of the Space Chemistry Symposium series since 2017, under the umbrella of the American Chemical Society. One of the first scientific papers at the field was published by InnoStudio in Nature Reviews Chemistry (2017).

In December 2019, InnoStudio was the first in the world to carry out nanomolecular chemical synthesis experiments on the International Space Station, which provided promising results for the development and manufacturing of novel active ingredients for the pharmaceutical, cosmetics, and agrochemical sectors. InnoStudio, together with CycloLab was also the first to investigate the possible effects of microgravity on the remdesivir-SBECD interaction, one of the most promising drugs for the treatment of COVID-19.